Acomplia (Acomplia) is a new miraculous multifunctional diet pill.

According to a report published by the Journal of the American Medical Association,

Accomplia

• produces sustained weight loss
• helps to quit smoking
• improves blood makers
• improves high-density lipoprotein (HDL) cholesterol and triglyceride levels

What is Acomplia?

• Acomplia (Acomplia) is the first in a new class of therapeutic agents called Cannabinoid-1 Receptor Blockers (CB1).

• Acomplia is used in the treatment of obesity and related conditions.

How does Acomplia work?

• Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle1

• Acomplia switches off the same brain circuits that make people hungry when they smoke cannabis

• CB1 receptor blockade with Acomplia acts to decrease the overactivity of the endocannabinoid system (EC system)2,3. The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism.

What is Acomplia used for?

• Acomplia is used complementary to diet and exercise to treat obese or overweight patients who suffer from Type 2 diabetes and abnormal levels of fat in the blood

• Acomplia can also prevent the risk of cardiovascular disease

• Patients with large waist circumference (102 cm in men and 88 cm in women) will mostly benefit from taking the drug.

Does Acomplia also aid smoking cessation?

Clinical trials have shown that heavy smokers, after being on a regular supplement of Acomplia, have stopped smoking altogether. Smokers usually do not stop smoking for fear of weight-gain, which can be highly discouraging. However since Acomplia works on the overeating and smoking factors simultaneously such problems wouldn't arise.

What are the side effects of Acomplia?

The most common side effects for Acomplia are:

* feeling nauseous and, occasionally, vomiting;
* diarrhoea;
* headache and dizziness; and
* feeling irritable and restless — less commonly, it can produce anxiety and depression.

Those who take the lower dosage of 10mg are less likely to experience any side effects. As with all medications, it is necessary to balance the benefits achieved against the small risk of some adverse effects.

One of the problems is that Acomplia is designed to change your mood. Before taking it, you enjoyed eating. Now you find you do not want to eat as much. Obviously, this helps you to maintain momentum on the diet. You may also be healthier because it is easier to quit smoking and give up recreational drugs. The difficulty some people face is reconciling their hopes with reality. They begin with the best intentions of losing weight and rebuilding self esteem, but when the expected results do not come within days, they first grow anxious and then depressed.

This is a not unexpected result, but Acomplia may be a factor in making such emotions seem stronger. The suggestion is also made that people do not gain the same emotional satisfaction from exercising and so lose motivation more rapidly. All weight loss is to some extent a test of character. No matter how much the medication may help you to feel less hungry, you have to take the decision to respond by eating less and eating more healthy food. Similarly, even though you may feel that the exercise is not working as quickly as you had hoped, you cannot give up. Exercise burns the calories. It speeds up the weight loss.

The drug, marketed in Europe as Acomplia, may ultimately be sold in the United States as Zimulti -- but that day appears several years off after an FDA advisory panel voted against sale of rimonabant in summer 2007 out of concern over its depressive side effects.

The Zimulti Acomplia Report, updated daily, will track the continuing efforts of Sanofi to get rimonabant approved for sale in the U.S. The Zimulti Acomplia Report also will provide news and reviews related to rimonabant so those eager to try this new anti-obesity drug will have the latest information on availability, weight-loss results and side-effects.

The German state insurance system earlier classified Acomplia a life-style drug and rejected reimbursing patients, and the French government has agreed to provide partial coverage only for obese (not simply overweight) patients who also have inadequately controlled type 2 diabetes.

Acomplia was approved by Brazil for use "as an adjunct to diet and exercise for the treatment of obese patients (BMI more than 30) or overweight patients (BMI more than 27) with associated risk factors, such as type 2 diabetes or dyslipidemia."